Tag Archive for: Therapeutics

Curve Therapeutics continues to enhance leadership team with appointment of Rab Prinjha as Chief R&D Officer

Deep expertise in leading drug discovery programs across oncology, neuroscience and epigenetics Will drive advancement of Curve’s rich pipeline of first-in-class therapeutic assets Builds on recent leadership team appointments, including Andre Hoekema as Chair of the Board Southampton, UK, 9 October 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a […]

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investors Oncode Oncology Bridge Fund, Swanbridge and BOM Flindr discovers and develops precision oncology therapeutics with the potential to eradicate tumors in specific patient populations Lead asset is a […]

AstronauTx and STORM recognised at inaugural One Nucleus Awards

Congratulations to our clients AstronauTx and STORM Therapeutics, which were recognised at the inaugural One Nucleus Awards in London in March.  AstronauTx scooped the Best Performing Primary R&D Company of the Year Award, while STORM won the One Nucleus Boston Bootcamp competition aimed at getting companies “US-ready”.  AstronauTx beat off strong competition to win the […]

Optimum TV launches amid green shoots from the biotech markets 

The nights are getting shorter and the green shoots of spring are emerging – and it’s an exciting time for Optimum Strategic Communications as it launches Optimum TV! Our associate director and former national newspaper journalist Stephen Adams will be presenting regular YouTube episodes showcasing our clients’ amazing work.    Heidelberg grabs orphan designation  Heidelberg […]

Curve Therapeutics April 2024 Conference Attendance

Southampton, UK, 21 March 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces activity at the following scientific and investor conferences during April 2024. Read more…